OBN: Supporting the UK’s Emerging Life Science R&D Companies

OBN is the organiser of BioTrinity.  OBN is the membership association supporting and bringing together the UK’s emerging life science R&D companies, their corporate partners and their investors. Our member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advisory, and advocacy activities and we are a source of industry information.

Partnering is achieved through the annual two-day BioTrinity - Europe's Premier biopartnering  and investor conference, the largest biopartnering conference in the UK, and the 3rd largest biopartnering conference in Europe.

Networking is achieved through a regular series of BioTuesdays, OBN's flagship evening networking events which typically feature 3-5 speakers talking on a topic of business, finance or scientific interest. They are typically attended by 80-120 delegates from across the Golden Triangle.  About 10 BioTuesdays take place annually in Oxford, Didcot, London, Basingstoke and Cambridge. OBN also arrange events for social networking: The OBN Summer Drinks and the OBN Christmas Networking Dinner. OBN also organises the Senior Exec Breakfast Club (SEBC), a unique forum for exclusive networking between the CXO peers of R&D companies, at quarterly events in Oxford, London and Cambridge.

Group Purchasing is achieved through OBN's comprehensive group Purchasing Scheme, which offers nearly 40 deals for R&D companies including over 10 laboratory related deals. OBN's Full Member companies achieve substantial savings on lab supplies, dry ice, gases and other commodity areas and services.  Some of our deals generate savings average a 40% discount of list price, making them an effective one-stop shop to control costs.

Find out more about OBN

 

 





BioTrinity 2013 highlights
877 delegates from 28 countries
520 companies
168 speakers
86 company presentations
1679 scheduled one-to-one meetings
97 investors from 11 countries
66 exhibitors
32 global pharma/corporate venture